

Jeffrey T Guptill

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2543934/publications.pdf>

Version: 2024-02-01

43
papers

1,432
citations

471061

17
h-index

344852

36
g-index

44
all docs

44
docs citations

44
times ranked

1391
citing authors

#	ARTICLE	IF	CITATIONS
1	Anti- μ sk antibody myasthenia gravis: Clinical findings and response to treatment in two large cohorts. <i>Muscle and Nerve</i> , 2011, 44, 36-40.	1.0	289
2	Update on muscle-specific tyrosine kinase antibody positive myasthenia gravis. <i>Current Opinion in Neurology</i> , 2010, 23, 530-535.	1.8	146
3	Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic. <i>Journal of the Neurological Sciences</i> , 2020, 412, 116803.	0.3	110
4	B cells in the pathophysiology of myasthenia gravis. <i>Muscle and Nerve</i> , 2018, 57, 172-184.	1.0	87
5	COVID-19-associated risks and effects in myasthenia gravis (CARE-MG). <i>Lancet Neurology</i> , The, 2020, 19, 970-971.	4.9	85
6	Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders. <i>Lancet Neurology</i> , The, 2022, 21, 176-188.	4.9	74
7	Effect of therapeutic plasma exchange on immunoglobulins in myasthenia gravis. <i>Autoimmunity</i> , 2016, 49, 472-479.	1.2	71
8	Antagonism of the Neonatal Fc Receptor as an Emerging Treatment for Myasthenia Gravis. <i>Frontiers in Immunology</i> , 2019, 10, 3052.	2.2	54
9	Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis. <i>Neurotherapeutics</i> , 2016, 13, 118-131.	2.1	53
10	Characterization of B cells in muscle-specific kinase antibody myasthenia gravis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e77.	3.1	49
11	Phase 1 Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Escalating Dose and Repeated Doses of CN-105 in Healthy Adult Subjects. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 770-776.	1.0	35
12	Cost analysis of myasthenia gravis from a large U.S. insurance database. <i>Muscle and Nerve</i> , 2011, 44, 907-911.	1.0	33
13	A Retrospective study of complications of therapeutic plasma exchange in myasthenia. <i>Muscle and Nerve</i> , 2013, 47, 170-176.	1.0	30
14	Obese Children Require Lower Doses of Pantoprazole Than Nonobese Peers to Achieve Equal Systemic Drug Exposures. <i>Journal of Pediatrics</i> , 2018, 193, 102-108.e1.	0.9	24
15	Patient demographics and health plan paid costs in chronic inflammatory demyelinating polyneuropathy. <i>Muscle and Nerve</i> , 2014, 50, 47-51.	1.0	23
16	B10 Cell Frequencies and Suppressive Capacity in Myasthenia Gravis Are Associated with Disease Severity. <i>Frontiers in Neurology</i> , 2017, 8, 34.	1.1	23
17	Tacrolimus inhibits Th1 and Th17 responses in MuSK-antibody positive myasthenia gravis patients. <i>Experimental Neurology</i> , 2019, 312, 43-50.	2.0	23
18	Establishment of normative ranges of the healthy human immune system with comprehensive polychromatic flow cytometry profiling. <i>PLoS ONE</i> , 2019, 14, e0225512.	1.1	20

#	ARTICLE	IF	CITATIONS
19	The Duke myasthenia gravis clinic registry: description and demographics. <i>Muscle and Nerve</i> , 2021, 63, 209-216.	1.0	20
20	Construction and validation of the chronic acquired polyneuropathy patient-reported index (CAPRI): A disease-specific, health-related quality-of-life instrument. <i>Muscle and Nerve</i> , 2016, 54, 9-17.	1.0	17
21	Imbalance in T follicular helper cells producing IL-17 promotes pro-inflammatory responses in MuSK antibody positive myasthenia gravis. <i>Journal of Neuroimmunology</i> , 2020, 345, 577279.	1.1	17
22	Classical Complement Pathway Inhibition in a Human-on-Chip Model of Autoimmune Demyelinating Neuropathies. <i>Advanced Therapeutics</i> , 2022, 5, .	1.6	17
23	Clinical outcome measures following plasma exchange for MG exacerbation. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 2114-2119.	1.7	14
24	Assessment of the effects of lacosamide on sleep parameters in healthy subjects. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2015, 25, 155-159.	0.9	13
25	Knowledge and perceptions of the COVID-19 pandemic among patients with myasthenia gravis. <i>Muscle and Nerve</i> , 2021, 63, 357-364.	1.0	13
26	Reliability of the triple-timed up-and-go test. <i>Muscle and Nerve</i> , 2018, 57, 136-139.	1.0	11
27	Normative dataset for plasma cytokines in healthy human adults. <i>Data in Brief</i> , 2021, 35, 106857.	0.5	11
28	Perioperative Outcomes of Thymectomy in Myasthenia Gravis: A Thoracic Surgery Database Analysis. <i>Annals of Thoracic Surgery</i> , 2022, 113, 904-910.	0.7	11
29	Inhibition of the transcription factor ROR- γ reduces pathogenic Th17 cells in acetylcholine receptor antibody positive myasthenia gravis. <i>Experimental Neurology</i> , 2020, 325, 113146.	2.0	10
30	The clinical need for clustered AChR cell-based assay testing of seronegative MG. <i>Journal of Neuroimmunology</i> , 2022, 367, 577850.	1.1	9
31	Randomized phase 2 study of ACE083, a muscle-promoting agent, in facioscapulohumeral muscular dystrophy. <i>Muscle and Nerve</i> , 2022, 66, 50-62.	1.0	8
32	Marked clinical and jitter improvement after eculizumab in refractory myasthenia. <i>Muscle and Nerve</i> , 2017, 56, E16-E18.	1.0	5
33	Validation of the triple timed up-and-go test in Lambert-Eaton myasthenia. <i>Muscle and Nerve</i> , 2019, 60, 292-298.	1.0	5
34	Population Pharmacokinetics and Exploratory Exposure-Response Relationships of Diazepam in Children Treated for Status Epilepticus. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2018, 7, 718-727.	1.3	4
35	Cellular changes in eculizumab early responders with generalized myasthenia gravis. <i>Clinical Immunology</i> , 2021, 231, 108830.	1.4	4
36	Identifying a patient-centered outcome measure for a comparative effectiveness treatment trial in myasthenia gravis. <i>Muscle and Nerve</i> , 2022, 65, 75-81.	1.0	4

#	ARTICLE	IF	CITATIONS
37	Adaptive immune response to therapy in hmgcr autoantibody myopathy. Muscle and Nerve, 2016, 53, 313-317.	1.0	2
38	Comparative effectiveness clinical trials to advance treatment of myasthenia gravis. Annals of the New York Academy of Sciences, 2018, 1413, 69-75.	1.8	2
39	Reduced plasmablast frequency is associated with seronegative myasthenia gravis. Muscle and Nerve, 2021, 63, 577-585.	1.0	2
40	Treatment Patterns and Costs of Chronic Inflammatory Demyelinating Polyneuropathy: A Claims Database Analysis. American Health and Drug Benefits, 2019, 12, 127-135.	0.5	2
41	Adverse Reactions in a Phase 1 Trial of the Anti-Malarial DM1157: An Example of Pharmacokinetic Modeling and Simulation Guiding Clinical Trial Decisions. Infectious Diseases and Therapy, 2022, 11, 841-852.	1.8	2
42	Emerging Subspecialties in Neurology: Clinical development. Neurology, 2013, 80, e4-e7.	1.5	0
43	Management/Treatment of Lambert-Eaton Myasthenic Syndrome. Current Treatment Options in Neurology, 2021, 23, 1.	0.7	0